Authors: Resbeut, M Fondrinier, E Fervers, B Haie-Meder, C Bataillard, A Lhomme, C Asselain, B Basuyau, JP Bremond, A Castaigne, D Dubois, JB Houvenaeghel, G Lartigau, E Leblanc, E Sastre-Garaud, X Ternier, F Guastalla, JP Chauvergne, J

Citation: M. Resbeut et al., Carcinoma of the cervix, BR J CANC, 84, 2001, pp. 24-30

Authors: Joly, F Heron, JF Kerbrat, P Chauvergne, J Rios, M Mayer, F Chinet-Charrot, P Goupil, A Lebrun-Jezekova, D Vennin, D Lhomme, C Mace-Lesec'h, J Crouet, H

Citation: F. Joly et al., High-dose platinum versus standard dose in advanced ovarian carcinoma: A randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC), GYNECOL ONC, 78(3), 2000, pp. 361-368

Authors: Lhomme, C Fumoleau, P Fargeot, P Krakowski, Y Dieras, V Chauvergne, J Vennin, P Rebattu, P Roche, H Misset, JL Lentz, MA Van Glabbeke, M Matthieu-Boue, A Mignard, D Chevallier, B

Citation: C. Lhomme et al., Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix, J CL ONCOL, 17(10), 1999, pp. 3136-3142

Authors: Lhomme, C Vennin, P Callet, N Lesimple, T Achard, JL Chauvergne, J Luporsi, E Chinet-Charrot, P Coudert, B Couette, JE Guastalla, JP Lebrun, D Ispas, S Blumberg, J

Citation: C. Lhomme et al., A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study, GYNECOL ONC, 75(2), 1999, pp. 187-193

Authors: Haie-Meder, C Fervers, B Chauvergne, J Fondrinier, E Lhomme, C Guastalla, JP Resbeut, M

Citation: C. Haie-meder et al., Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR, B CANCER, 86(10), 1999, pp. 829-841